Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study.
- DOI
- 10.1007/s00415-026-13675-7
- Published
- 2026 Mar 25
- Container
- Journal of neurology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s00415-026-13675-7,
title = {Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study.},
author = {Montalban X and Hohlfeld R and Pozzilli C and Freedman MS and Sprenger T and Fox RJ and Havrdova EK and Lublin F and Huang D and Raghavan N and Wong J and Vaclavkova A and Dukovski J and Linscheid P and Burcklen M and Kappos L},
year = {2026},
journal = {Journal of neurology},
doi = {10.1007/s00415-026-13675-7},
url = {https://doi.org/10.1007/s00415-026-13675-7}
}RIS
TY - JOUR TI - Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study. AU - Montalban X AU - Hohlfeld R AU - Pozzilli C AU - Freedman MS AU - Sprenger T AU - Fox RJ AU - Havrdova EK AU - Lublin F AU - Huang D AU - Raghavan N AU - Wong J AU - Vaclavkova A AU - Dukovski J AU - Linscheid P AU - Burcklen M AU - Kappos L PY - 2026 JO - Journal of neurology DO - 10.1007/s00415-026-13675-7 UR - https://doi.org/10.1007/s00415-026-13675-7 ER -
APA
X, M., R, H., C, P., MS, F., T, S., RJ, F., EK, H., F, L., D, H., N, R., J, W., A, V., J, D., P, L., M, B., & L, K. (2026). Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study.. Journal of neurology. https://doi.org/10.1007/s00415-026-13675-7
Source records
- pubmed · retrieved 2026-09-26T06:54:52.475Z